66
Participants
Start Date
October 25, 2023
Primary Completion Date
May 15, 2026
Study Completion Date
May 15, 2026
Biopsy Procedure
Undergo biopsy
Biospecimen Collection
Undergo collection of blood and urine sample
Cabozantinib
Given PO
Computed Tomography
Undergo CT
Ipilimumab
Given IV
Magnetic Resonance Imaging
Undergo MRI
Nivolumab
Given IV
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
MedStar Georgetown University Hospital, Washington D.C.
National Cancer Institute Developmental Therapeutics Clinic, Bethesda
National Institutes of Health Clinical Center, Bethesda
University of Virginia Cancer Center, Charlottesville
VCU Massey Comprehensive Cancer Center, Richmond
UNC Lineberger Comprehensive Cancer Center, Chapel Hill
University of Florida Health Science Center - Gainesville, Gainesville
Vanderbilt University/Ingram Cancer Center, Nashville
Ohio State University Comprehensive Cancer Center, Columbus
Washington University School of Medicine, St Louis
Siteman Cancer Center-South County, St Louis
University of Oklahoma Health Sciences Center, Oklahoma City
M D Anderson Cancer Center, Houston
Huntsman Cancer Institute/University of Utah, Salt Lake City
Keck Medicine of USC Koreatown, Los Angeles
Los Angeles General Medical Center, Los Angeles
USC / Norris Comprehensive Cancer Center, Los Angeles
City of Hope Comprehensive Cancer Center, Duarte
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine
USC Norris Oncology/Hematology-Newport Beach, Newport Beach
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Smilow Cancer Hospital Care Center at Saint Francis, Hartford
Yale University, New Haven
Smilow Cancer Hospital Care Center-Trumbull, Trumbull
University Health Network-Princess Margaret Hospital, Toronto
National Cancer Institute LAO
UNKNOWN